AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10801752 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to stable ST-segment recovery
Number of subjects: 134
Study 8846930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta Estradiol (Estraderm TTS 100 plasters) for 24 weeks, with Chlormadinon 2 mg from day 16 to 28 of the fourth cycle
Number of subjects: 25
Study 1298792 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-back/ultrasound preparation
Number of subjects: 34
Study 1298792 — intervention group
Group type: COMPARATOR
Intervention: Step-back preparation
Number of subjects: 34
Study 6375802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g intravenous injection)
Number of subjects: 160
Study 6375802 — intervention group
Group type: COMPARATOR
Intervention: Control (no cefuroxime)
Number of subjects: 160
Study 6375802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 160
Study 6375802 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 31523680 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization training
Number of subjects: 27
Study 31523680 — intervention group
Group type: EXPERIMENTAL
Intervention: Equilibrium training
Number of subjects: 27
Study 31523680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 30464398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongfu powder
Number of subjects: 102
Study 30464398 — intervention group
Group type: COMPARATOR
Intervention: Mosapride
Number of subjects: 102
Study 26999011 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Breast Feeding (EBF)
Number of subjects: 1629
Study 24786356 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy 30 mg
Number of subjects: 165
Study 24786356 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy 100 mg
Number of subjects: 165
Study 24786356 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib monotherapy 500 mg
Number of subjects: 165
Study 24786356 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 100 mg in combination with atorvastatin 10 mg
Number of subjects: 165
Study 24786356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 24786356 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 165
Study 22430452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated corticosteroids
Number of subjects: 644
Study 20405165 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine (RAI) (n = 24)
Number of subjects: 46
Study 20405165 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole (CBZ) (n = 22)
Number of subjects: 46
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more prophylactic antiemetics
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with ASA guidelines
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with ASPAN guidelines
Number of subjects: 0
Study 18633023 — intervention group
Group type: COMPARATOR
Intervention: <1 prophylactic antiemetic
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antiemetic administration
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication use
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe nausea
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional interference due to emetic symptoms
Number of subjects: 0
Study 18633023 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete control (CR and no moderate-severe nausea)
Number of subjects: 0
Study 15946427 — intervention group
Group type: EXPERIMENTAL
Intervention: halogenated anesthetic/oxygen/N2O mixture
Number of subjects: 50
Study 15946427 — intervention group
Group type: COMPARATOR
Intervention: halogenated anesthetic/oxygen/air mixture
Number of subjects: 50
Study 12594633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 25 mg/week
Number of subjects: 0
Study 12594633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 50 mg/week
Number of subjects: 0
Study 12594633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg/week
Number of subjects: 0
Study 12594633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg/week
Number of subjects: 0
Study 12594633 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg/week
Number of subjects: 0
Study 12594633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11783334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganrening Granule (GRN)
Number of subjects: 400
Study 11783334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 8813919 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled monitoring of bladder pressure (Group B)
Number of subjects: 53
Study 8813919 — intervention group
Group type: COMPARATOR
Intervention: Unmonitored patients (Group A)
Number of subjects: 53
Study 1593461 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain force task
Number of subjects: 0
Study 1593461 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintain position task
Number of subjects: 0
Study 1593461 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia of the radial nerve
Number of subjects: 0
Study 3939672 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg b.i.d. of terfenadine
Number of subjects: 560
Study 3939672 — intervention group
Group type: COMPARATOR
Intervention: 4 mg t.i.d. of chlorpheniramine (active control)
Number of subjects: 560
Study 3939672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 3939672 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 560
Study 31188704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest Redistribution (RR) with 30-s intraset rest and 90-s interset rest
Number of subjects: 12
Study 31188704 — intervention group
Group type: COMPARATOR
Intervention: Traditional sets with 120-s interset rest
Number of subjects: 12
Study 31188704 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest Redistribution (RR)
Number of subjects: 12
Study 29559697 — intervention group
Group type: EXPERIMENTAL
Intervention: Active fixation (screw) leads
Number of subjects: 326
Study 29559697 — intervention group
Group type: COMPARATOR
Intervention: Passive fixation (tine) leads
Number of subjects: 326
Study 27733098 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric microdosing (1 × 1.5 μl, 1 × 6 μl, or 2 × 3 μl of phenylephrine 2.5% and tropicamide 1.0%)
Number of subjects: 102
Study 27733098 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric microdosing (2 × 3 μl)
Number of subjects: 102
Study 27733098 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric saline self-delivery
Number of subjects: 102
Study 27733098 — intervention group
Group type: COMPARATOR
Intervention: Eyedropper doses of phenylephrine and tropicamide
Number of subjects: 102
Study 24322433 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US) at a frequency of 1 MHz with intensity of 1 W/cm
Number of subjects: 60
Study 24322433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (US) at the same frequency and intensity on 1:4 pulse ratio
Number of subjects: 60
Study 24322433 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 60
Study 22337156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced format consent documents (printed on 20-pound, cream-colored bond paper and presented in a blue folio)
Number of subjects: 499
Study 22337156 — intervention group
Group type: COMPARATOR
Intervention: Standard format consent documents (stapled set of photocopied pages)
Number of subjects: 499
Study 22337156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced format consent documents
Number of subjects: 499
Study 22337156 — intervention group
Group type: COMPARATOR
Intervention: Standard format consent documents
Number of subjects: 499
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG0 (Pathological complete response)
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG1 (Good regression)
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG2 (Moderate regression)
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG3 (Poor regression)
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG0
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG1
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG2
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG3
Number of subjects: 131
Study 20430458 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG1 vs TRG2 vs TRG3 (persistent disease)
Number of subjects: 131
Study 18377704 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (no controlled hypotension)
Number of subjects: 30
Study 18377704 — intervention group
Group type: COMPARATOR
Intervention: Group B (controlled hypotension)
Number of subjects: 30
Study 15782877 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-month reminder letter to have a Pap test (n=60,000)
Number of subjects: 90000
Study 15782877 — intervention group
Group type: COMPARATOR
Intervention: No reminder letter (n=30,000)
Number of subjects: 90000
Study 14744332 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 14744332 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 0
Study 12034516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tibolone 2.5 mg per day
Number of subjects: 165
Study 12034516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic combined regimen of transdermal oestrogen and progestogen
Number of subjects: 165
Study 12034516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent progesterone regimen
Number of subjects: 165
Study 9471928 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid arterial intima-media thickness measurement
Number of subjects: 146
Study 8869019 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrelin (glycoprotein IIb/IIIa receptor inhibitor)
Number of subjects: 0
Study 8869019 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of integrelin
Number of subjects: 0
Study 2357919 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up intervention (telephone calls and home visit)
Number of subjects: 60
Study 2357919 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (3-day educational program and review session)
Number of subjects: 60
Study 388400 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg tienilic acid
Number of subjects: 0
Study 388400 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg tienilic acid
Number of subjects: 0
Study 388400 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 0
Study 388400 — intervention group
Group type: EXPERIMENTAL
Intervention: tienilic acid and hydrochlorothiazide
Number of subjects: 0
Study 6309204 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium 10 mg
Number of subjects: 50
Study 6309204 — intervention group
Group type: COMPARATOR
Intervention: gallamine 20 mg
Number of subjects: 50
Study 29415697 — intervention group
Group type: EXPERIMENTAL
Intervention: WhiteTeeth app in addition to care as usual
Number of subjects: 146
Study 29415697 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 146
Study 28116306 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 0
Study 28116306 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25122928 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for preeclampsia including placental growth factor, mean arterial pressure, body mass index, consumption of ≥3 pieces of fruit per day, mean uterine artery resistance index
Number of subjects: 5623
Study 25122928 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model for early-onset preeclampsia including angiogenin/placental growth factor ratio, mean arterial pressure, any pregnancy loss <10 weeks, mean uterine artery resistance index
Number of subjects: 5623
Study 22409922 — intervention group
Group type: EXPERIMENTAL
Intervention: Honghua Injection
Number of subjects: 64
Study 22409922 — intervention group
Group type: COMPARATOR
Intervention: Control (routine Western medicine)
Number of subjects: 64
Study 20409690 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 1150
Study 20409690 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 1150
Study 18841081 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 51
Study 18841081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 51
Study 18841081 — intervention group
Group type: COMPARATOR
Intervention: No Stretching (NS)
Number of subjects: 51
Study 15969641 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 0
Study 15969641 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 0
Study 14500440 — intervention group
Group type: EXPERIMENTAL
Intervention: System of structured asthma care (the 3+ visit plan)
Number of subjects: 174
Study 14500440 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study 11910658 — intervention group
Group type: EXPERIMENTAL
Intervention: Alora
Number of subjects: 33
Study 11910658 — intervention group
Group type: COMPARATOR
Intervention: Evorel
Number of subjects: 33
Study 8695129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium (divided dose: 0.15 mg/kg followed by 0.1 mg/kg after 30 seconds)
Number of subjects: 200
Study 8695129 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg succinylcholine (preceded by 50 micrograms/kg d‐tubocurarine)
Number of subjects: 200
Study 8695129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium (divided dose)
Number of subjects: 200
Study 1524174 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration with 4.4 ml of 1:80,000 adrenaline and 2% lignocaine
Number of subjects: 20
Study 1524174 — intervention group
Group type: COMPARATOR
Intervention: Moffett's solution containing 1 ml of 1:1,000 adrenaline
Number of subjects: 20
Study 1524174 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration group
Number of subjects: 20
Study 6500458 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with small expander
Number of subjects: 21
Study 6500458 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with large expander
Number of subjects: 21
Study 6500458 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler without expander
Number of subjects: 21
Study 31420402 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade
Number of subjects: 0
Study 31420402 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Number of subjects: 0
Study 31420402 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29457512 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived network exposure to daily sugar-sweetened beverages
Number of subjects: 266
Study 29457512 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived network exposure to daily sweets
Number of subjects: 266
Study 29457512 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived network exposure to weekly vigorous exercise
Number of subjects: 266
Study 29457512 — intervention group
Group type: COMPARATOR
Intervention: Perceived network exposure to weekly moderate exercise
Number of subjects: 266
Study 26680699 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 399
Study 26680699 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 399
Study 24075236 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillomandibular fixation (MMF) screws
Number of subjects: 20
Study 24075236 — intervention group
Group type: COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Number of subjects: 20
Study 23123531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid treatment (4 weekly 2-hour sessions)
Number of subjects: 20
Study 23123531 — intervention group
Group type: COMPARATOR
Intervention: Monitoring Group (pain and sleep diary for 4 weeks)
Number of subjects: 20
Study 20209697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg every three hours, up to five doses)
Number of subjects: 50
Study 20209697 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg every three hours, up to five doses)
Number of subjects: 50
Study 20209697 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 50
Study 20209697 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 50
Study 18722968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 1% ropivacaine
Number of subjects: 40
Study 18722968 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of sterile water
Number of subjects: 40
Study 16038172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group A
Number of subjects: 331
Study 16038172 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group B
Number of subjects: 331
Study 16038172 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group C
Number of subjects: 331
Study 16038172 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis in group D
Number of subjects: 331
Study 16038172 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment for GERD in subgroup A1
Number of subjects: 331
Study 16038172 — intervention group
Group type: EXPERIMENTAL
Intervention: No outpatient treatment for GERD in subgroup A2
Number of subjects: 331
Study 12185449 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin I (30 ng kg(‐1) x min(‐1))
Number of subjects: 24
Study 12185449 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-Ser-Asp-Lys-Pro (AcSDKP; 1.12 micro g kg(‐1) x min(‐1))
Number of subjects: 24
Study 12185449 — intervention group
Group type: COMPARATOR
Intervention: Captopril (inhibition of angiotensin I converting enzyme)
Number of subjects: 24
Study 10561190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity markers (3 types)
Number of subjects: 313
Study 10561190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain relief scale
Number of subjects: 313
Study 10561190 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction scale
Number of subjects: 313
Study 10561190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management indexes (3 types)
Number of subjects: 313
Study 8684871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand trimethoprim‐sulfamethoxazole
Number of subjects: 20
Study 8684871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand and generic formulations of cephalexin and erythromycin‐sulfisoxazole
Number of subjects: 20
Study 8684871 — intervention group
Group type: COMPARATOR
Intervention: Generic antibiotic suspensions
Number of subjects: 20
Study 1725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 61
Study 1725543 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene
Number of subjects: 61
Study 1725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem + Hydrochlorothiazide/Triamterene
Number of subjects: 61
Study 1725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/Triamterene + Diltiazem
Number of subjects: 61
Study 1725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem as first choice
Number of subjects: 61
Study 1725543 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/Triamterene alone
Number of subjects: 61
Study 1725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/Triamterene added to Diltiazem
Number of subjects: 61
Study 1725543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem added to Hydrochlorothiazide/Triamterene
Number of subjects: 61
Study 7080884 — intervention group
Group type: EXPERIMENTAL
Intervention: 16‐item Binge Eating Scale
Number of subjects: 0
Study 7080884 — intervention group
Group type: EXPERIMENTAL
Intervention: 11‐item Cognitive Factors Scale
Number of subjects: 0
Study 29740842 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin for 3 months
Number of subjects: 54
Study 29740842 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 54
Study 27414973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PhC)
Number of subjects: 128
Study 27414973 — intervention group
Group type: COMPARATOR
Intervention: Standard nurse staff instructions (control)
Number of subjects: 128
Study 23475701 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 323
Study 23475701 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PRA in nonblacks
Number of subjects: 323
Study 23475701 — intervention group
Group type: EXPERIMENTAL
Intervention: PRA in blacks
Number of subjects: 323
Study 23258574 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 56
Study 23258574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20804941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 6
Study 20804941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 18060746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250mg twice a day for 3 days
Number of subjects: 27
Study 18060746 — intervention group
Group type: COMPARATOR
Intervention: Furagin 100mg three times a day for 7 days
Number of subjects: 27